40 results about "Monoclonal antibody production" patented technology

A method of increasing animal cell growth and monoclonal antibody production in an animal cell or cell culture includes the use of ultrasound at a frequency greater than about 1 MHz.

The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

The invention discloses an affinity purification method for reducing the content of host cell protein in monoclonal antibody production, which comprises the following steps: balancing an affinity chromatography medium by using a first equilibrium buffer solution to obtain a balanced affinity chromatography medium, and combining monoclonal antibody fermentation liquor with the balanced affinity chromatography medium; and then carrying out intermediate pre-elution and elution, and then carrying out final elution to remove host cell protein so as to obtain a monoclonal antibody, wherein the monoclonal antibody is a separated monoclonal antibody against human interferon alpha receptor 1 (IFNAR1), and comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3). The method is simple and easy to implement, amplification purification production can be carried out, the cell fermentation supernate does not need to be subjected to pretreatment, the elution sample yield is high, meanwhile, the HCP residual quantity is kept at a low level (the residual control quantity is not higher than 0.1%), and therefore the pressure for removing HCP in the subsequent purification step is relieved.

The present invention relates to anti-human NKX3.1 monoclonal antibody and its preparation method and application. The invention provides an anti-human NKX3.1 monoclonal antibody, and further provides the amino acid sequences of the variable regions of its heavy chain and light chain. On this basis, the antibody can be prepared by conventional genetic engineering methods. Compared with the traditional monoclonal antibody preparation method, the anti-human NKX3.1 recombinant antibody prepared by the genetic engineering method of the present invention has the advantages of known sequence, stable antibody properties, good repeatability, etc., and can specifically recognize human NKX3.1 protein , can be used for IHC immunohistochemical detection. And the standardized antibody production process avoids the risk factors that appear in the traditional monoclonal antibody production and storage process. Furthermore, on the basis of the amino acid sequence of the antibody provided by the present invention, one or more amino acid additions, deletions, substitutions, etc., can also be modified to obtain active fragments or conservative variants, in order to further improve the specificity and Affinity lays the groundwork.

The invention provides a method for increasing the production of monoclonal antibodies, comprising the following steps: (1) cloning and culturing hybridoma cells, and injecting the cultured hybridoma cells into animals; (2) feeding glucose solution to animals (3) collecting ascites antibody; (4) purifying the collected ascites antibody. In the present invention, after the animals are injected into the hybridoma cells, the mice start to be fed with the glucose solution mixed with pure water, and unexpected technical effects are obtained. The monoclonal antibody obtained by the method is equivalent, greatly reduces the cost of antibody production, greatly increases its economic benefits, and provides a new idea for the supply of raw materials in the IVD industry.